Corindus Vascular Robotics (CVRS) Stock Price, News & Analysis

Company Overview

Corindus Vascular Robotics develops and commercializes robotic systems designed to enhance the precision and safety of vascular interventions. Its core offering, the CorPath GRX System, enables interventional cardiologists and radiologists to perform percutaneous coronary and peripheral procedures from a protected cockpit, reducing occupational radiation exposure and improving catheter control during complex stent and balloon deployments.

The CorPath platform leverages proprietary robotics, software and imaging integration to translate a physician’s hand movements into precise, millimeter‐level motions for guidewire and catheter manipulation. The system has received multiple FDA clearances, including initial approval for neurovascular procedures and later expansion to percutaneous coronary intervention, as well as CE marking for use in European markets. Corindus works with leading medical centers and distributors to deploy its technology across the United States, Europe, the Middle East and Asia.

Founded in 2002 by Dr. Rafael Beyar and Elad Benjamin, Corindus is headquartered in Waltham, Massachusetts. Over its history, the company has focused on building clinical evidence around robotic‐assisted vascular interventions and has conducted numerous multi-center studies demonstrating reduced radiation exposure and consistent device placement compared with manual techniques. In April 2019, Corindus was acquired by Siemens Healthineers, underscoring the strategic importance of robotics in advancing image-guided therapy.

Key Stats

• Today's Range: $4.27 to $4.27
• 50-Day Range: $4.27 to $4.27
• 52-Week Range: $0.78 to $4.40
• Volume: N/A
• Average Volume: 1.99 million shs
• Market Capitalization: $891.08 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CVRS Stock Analysis - Frequently Asked Questions

How have CVRS shares performed this year?

Corindus Vascular Robotics' stock was trading at $4.27 at the start of the year. Since then, CVRS shares have increased by 0.0% and is now trading at $4.27.

How were Corindus Vascular Robotics' earnings last quarter?

Corindus Vascular Robotics Inc (NYSEAMERICAN:CVRS) announced its quarterly earnings results on Tuesday, August, 7th. The medical equipment provider reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.05) by $0.01. The medical equipment provider had revenue of $1.67 million for the quarter, compared to the consensus estimate of $3 million.

How do I buy shares of Corindus Vascular Robotics?

Shares of CVRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Corindus Vascular Robotics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Corindus Vascular Robotics investors own include Amarin (AMRN), TransEnterix (TRXDW), Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Helios and Matheson Analytics (HMNY) and Meta Platforms (META).

Company Calendar

• Last Earnings: 8/07/2018
• Today: 7/19/2025

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: Medical Appliances & Equipment
• Sub-Industry: Medical Equipment
• Current Symbol: NYSEAMERICAN:CVRS
• Previous Symbol: NYSEMKT:CVRS
• CIK: N/A
• Web: www.corindus.com
• Phone: +1-508-6533335
• Fax: N/A
• Employees: 90
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 208,685,000
• Free Float: N/A
• Market Cap: $891.08 million
• Optionable: Not Optionable
• Beta: N/A